Cancer
PARP inhibitor shows promise in treatment of breast, ovarian cancers
P-S6 potential ‘functional’ biomarker in BRAF-mutant melanoma
Suppression of the phosphorylation of the protein S6 after the initiation of RAF inhibitor therapy may serve as a functional biomarker to guide the treatment of patients with BRAF-mutant melanoma, according to study results presented at the International Conference on Molecular Targets and Cancer Therapeutics.
Antibody-drug conjugate demonstrated activity against guanylyl cyclase C in pancreatic cancer
New technology accurately detected BRAF mutations in tissue samples
A new molecular diagnostic prototype platform detected BRAF mutations in cancer tissue samples faster and more accurately vs. Clinical Laboratory Improvement Amendments-approved lab results, according to findings presented at the International Conference on Molecular Targets and Cancer Therapeutics.